Clinical Trial

Low-Protein Diet With Low-Protein Foods Versus a LPD Without LP Foods in Patients With Chronic Kidney Disease (CKD)

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated January 29, 2025 (before its estimated March 2026 completion). Its status may not reflect the trial's current state.
Summary
The KDOQI 2020 - Clinical practice guideline for nutrition in chronic kidney disease (CKD) -recommends protein restriction to reduce the risk of end-stage renal disease/death and improve quality of life, a low protein diet providing 0.55-0.60g dietary protein/ kg body weight/day is recommended. FLAVIS® is a product line of hypoprotein foods specially developed for the treatment of CKD.The use of low-protein foods may facilitate the achievement of nutritional goals in terms of protein intake and help patients to follow a low-protein diet.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2022-08-03; most recent amendment 2025-01-27.
Status change: Not Yet Recruiting → Recruiting 2023-09-06
Trial Details
NCT Number NCT05489120
Lead Sponsor Dr. Schär AG / SPA
Collaborators: Slb Pharma
Conditions Chronic Kidney Disease Stage 3B, Chronic Kidney Disease stage4, Chronic Kidney Disease Stage 5, Chronic Kidney Disease Stage 3A
Enrollment 244 participants
Start Date 2022-11-06
Primary Completion 2026-03 (estimated)
Study Completion 2026-03 (estimated)
Updated on ClinicalTrials.gov 2025-01-29